Wilburt Remedies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 14-12-2024
- Paid Up Capital ₹ 0.10 M
as on 14-12-2024
- Company Age 12 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -12.01%
(FY 2021)
- Profit -11.59%
(FY 2021)
- Ebitda -12.66%
(FY 2021)
- Net Worth 34.26%
(FY 2021)
- Total Assets 32.90%
(FY 2021)
About Wilburt Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pramod Patil, Rajesh Jat, Prashant Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232MP2012PTC028524
- Company No.
028524
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Wilburt Remedies?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Patil  | Director | 25-May-2012 | Current |
| Rajesh Jat | Director | 25-May-2012 | Current |
| Prashant Singh | Director | 11-Jul-2014 | Current |
| Dharamveer Shaktawat | Director | 11-Jul-2014 | Current |
Financial Performance of Wilburt Remedies.
Wilburt Remedies Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 12.01% decrease. The company also saw a substantial fall in profitability, with a 11.59% decrease in profit. The company's net worth Soared by an impressive increase of 34.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wilburt Remedies?
In 2021, Wilburt Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wilshire Pharmaceuticals Private LimitedActive 14 years 3 monthsPramod Patil, Rajesh Jat and 1 more are mutual person
Willcare Lifesciences Private LimitedActive 13 years 9 monthsRajesh Jat and Prashant Singh are mutual person
Wilburt Pharmaceuticals Private LimitedActive 3 months 17 daysPramod Patil and Rajesh Jat are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wilburt Remedies?
Wilburt Remedies has a workforce of 67 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wilburt Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wilburt Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
